Funding round
Enveda Series E
Enveda, which works in drug discovery and development in Boulder, raised $311M in a Series E round announced on 23 Sep 2026, led by Catalio Capital Management, at a $2.00B post-money valuation. 17 firms took part. It is Enveda's sixth venture round on record; the one before was a Series D in Sep 2025.
$311M
Amount raised
$2.00B
Post-money valuation
17
Investors
1 lead
16%
Stake sold
new money over the post-money
Valuation
What this round says about the price
This round priced Enveda at $2.00B after the new money. The $311M bought investors about 16% of the company. It came 12 months after Enveda's Series D. It is 44% of the $715M Enveda has raised in the venture rounds on record. No later venture round is on record for Enveda.
Enveda's funding rounds
Enveda has 6 venture rounds on record. This one is highlighted.
- Seed 27 Dec 2020, led by True Ventures $4.9M
- Series A 22 Jun 2021, led by Lux Capital $51M
- Series B 21 Dec 2022, led by Dimension $68M
- Series C 21 Nov 2024, led by Kinnevik and FPV Ventures $130M
- Series D 4 Sep 2025, led by Premji Invest $150M
- Series E this round 23 Sep 2026, led by Catalio Capital Management $311M$2.00B post-money
Investors
Who put money in
Catalio Capital Management led the round with 16 other firms.
Lead investor
- backs 57 venture-backed companies new investor
Also in the round
- Durable Capital Partners backs 39 venture-backed companies new investor
- ICONIQ new investor
- Lightspeed new investor
- Surveyor Capital new investor
- T. Rowe Price Investment Management new investor
- backs 48 venture-backed companies new investor
- Sovereign Wealth Fund new investor
- Alderline Group new investor
- Baillie Gifford new investor
- Premji Invest backs 50 venture-backed companies new investor
- backs 39 venture-backed companies new investor
- backs 158 venture-backed companies new investor
- Kinnevik backs 55 venture-backed companies new investor
- backs 24 venture-backed companies new investor
- backs 16 venture-backed companies new investor
- Lux Capital backs 194 venture-backed companies new investor
Use of proceeds
What the money is for
According to the announcement, the money goes to product development and scaling operations.
- Product development
- Scaling operations
Comparable rounds
How it compares
5 Series E rounds in Biotechnology within a year either side disclosed an amount; the median was $50M, and this round was 6.2 times the median. The closest in time, other companies' Series E rounds in Biotechnology:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| LifeMine Biotechnology | 7 Aug 2026 | $263M | not disclosed | Milky Way Investments |
| Biotechnology | 25 Aug 2026 | $50M | not disclosed | not named |
| Element Biosciences Biotechnology | 9 Jun 2026 | $175M | not disclosed | Samsung Electronics |
| Biotechnology | 15 Apr 2026 | $40M | $1.00B | not named |
| Biotechnology | 8 Jan 2026 | $48M | not disclosed | ARCH Venture Partners and M Ventures |
Sources
Where this comes from
Reported by 5 sources.
Questions
Frequently asked
How much did Enveda raise in its Series E round?
Enveda raised $311M in its Series E round, announced in Sep 2026.
Who led Enveda's Series E round?
Catalio Capital Management led it, with Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital and T. Rowe Price Investment Management and 11 more.
What was Enveda's valuation at the Series E round?
$2.00B post-money.
How does it compare with other Series E rounds in Biotechnology?
5 Series E rounds in Biotechnology within a year either side disclosed an amount; the median was $50M, and this round was 6.2 times the median.